Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis.
about
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysisInterferon beta versus glatiramer acetate for relapsing-remitting multiple sclerosisThe Effect of Disease Modifying Therapies on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-AnalysisOptimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosisPharmacological Approaches to Delaying Disability Progression in Patients with Multiple SclerosisThe Relationship Between Brain MR Spectroscopy and Disability in Multiple Sclerosis: 20-Year Data from the U.S. Glatiramer Acetate Extension Study.Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological SocietyA pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis.Case Report: Two Cases of Nicolau Syndrome Associated with Glatiramer Acetate.Once-daily glatiramer acetate decreases magnetic resonance imaging disease activity in Japanese patients with relapsing-remitting multiple sclerosis.Diagnosis of exclusion: a case report of probable glatiramer acetate-induced eosinophilic myocarditis.Two decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing-remitting multiple sclerosis treatment.Risk stratification and mitigation multiple sclerosis.Current perspectives on interferon Beta-1b for the treatment of multiple sclerosisMultiple sclerosis: overview of disease-modifying agentsThe role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis.Glatiramer Acetate 40 mg/mL in Relapsing-Remitting Multiple Sclerosis: A Review.2014 multiple sclerosis therapeutic update.Medication use in a large international sample of people with multiple sclerosis: associations with quality of life, relapse rate and disabilityInterferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.Modelling and sample size reestimation for longitudinal count data with incomplete follow up.Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple SclerosisMultiple sclerosis: Five new things.The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple SclerosisSafety and Efficacy of Fingolimod and Natalizumab in Multiple Sclerosis After the Failure of First-Line Therapy: Single Center Experience Based on the Treatment of Forty-Four Patients.Time course of glatiramer acetate efficacy in patients with RRMS in the GALA study.Glatiramer acetate: a review of its use in patients with relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis.Established and novel disease-modifying treatments in multiple sclerosis.Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis.Metabolic and safety issues for multiple sclerosis pharmacotherapy--opportunities for personalised medicine.Current management of relapsing-remitting multiple sclerosis.Meta-analysis of adverse events in recent randomized clinical trials for dimethyl fumarate, glatiramer acetate and teriflunomide for the treatment of relapsing forms of multiple sclerosis.Effectiveness of multiple sclerosis treatment with current immunomodulatory drugs.Glatiramer acetate: long-term safety and efficacy in relapsing-remitting multiple sclerosis.Development of Glatopa® (Glatiramer Acetate): The First FDA-Approved Generic Disease-Modifying Therapy for Relapsing Forms of Multiple Sclerosis.Considerations in the development of generic disease therapies for multiple sclerosis.Predictors of Response to Multiple Sclerosis Therapeutics in Individual Patients.Optimization and stratification of multiple sclerosis treatment in fast developing economic countries: a perspective from Qatar.[Immunotherapy and infectious issues in multiple sclerosis. Self-injectable and oral drugs for immunotherapy].Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense "black holes": a post hoc magnetic resonance imaging analysis.
P2860
Q24187126-07CBD36C-C12F-4D88-9970-49538A1DEE27Q24194800-CD9E066C-716A-4DA3-921C-20AC9C4CF15AQ26773978-271B5BC8-0180-44DC-AA36-3A558AE0C758Q26777686-57F29EC9-9659-4020-AE21-271AF78E5C6AQ27000269-37B6A33B-6226-4120-81DE-B15F76F49410Q31100010-C1E3AD3A-1DA5-4F56-9203-72D04430B6F3Q31123447-C9685346-CBAB-4932-BAD4-410B1EEE64DAQ33742905-5BC622E0-299E-4E3D-9097-A85E976AE61EQ33769224-E017282B-6B7E-4781-AEFC-128672685D4DQ33835877-9120D10E-B422-4605-BA37-576D1A3FCFCEQ33930225-DAED5574-3E89-4A11-B333-AB35AA33A8D6Q34090086-99F3BD9C-5B57-474F-A476-C9B7B85F061EQ34155446-EA950EB3-1F33-4834-A8EA-B488BC02EB91Q34253488-F2C16D14-A93F-4ED5-8E2D-7D4ECCBDC325Q34342662-F70CA3CE-2B84-47BC-B0DD-4B45A051B942Q34468304-4A703E27-6C4C-4FF7-BB91-EE57D62947B3Q34473419-BE5B6A5C-9A2D-4991-BB7E-33A9AB2892B3Q34661089-9B738CFA-F95A-4F16-9F56-AFD1799597A0Q35866381-DE557E15-D237-4CAF-B19E-AE5A4155A1C5Q36202727-86922475-DED7-4478-882E-3011730E3BF8Q36410659-CAB38321-1119-43DA-ADA4-33C316112327Q36484448-EC6322C0-F043-45DB-8B91-AB5EFBC3DE08Q37251695-80C0C879-62E5-4139-AA37-49015CB9511AQ37320255-AF78E992-8AB9-4D78-A5A6-DD804905A028Q37422818-A38107C9-3804-4D11-ADE2-4719DDA3CF4BQ37633582-F9DA1342-8F4A-4AD3-A127-D4D2A255162AQ38152977-1D34C814-2622-4AFA-9421-8F322B955E0FQ38180157-1773FE08-7243-429E-9E6B-528D05C6E87BQ38192006-DAFDC8AF-5266-45DE-91C5-1F472C742B73Q38218692-571D564D-7292-4BB8-9F38-1F01367E1702Q38258818-A07AF0D2-AF0D-4B37-8C8B-26D2C652F6D7Q38267110-4550524B-FAC2-4050-B8B3-8BCC47B7A887Q38315992-A2783355-C68C-4C43-9515-A59876A4E7DCQ38449394-B4D4986B-404F-4E0A-ABE0-8A899F4509ACQ38636620-F9F816F1-52B4-4660-81D8-A81EDC061DB5Q38940760-B4258599-4A74-4F77-82A8-30C1D9AC70C3Q38960854-0A1801E1-E7D9-49EA-8B89-D225E04CFDCAQ39021942-0FEFBD9B-459D-4E15-AC60-3F4F2BDD4ACFQ41102110-D689E1DE-8B12-41C7-BEDA-E500BD83C3B1Q41647429-0F4BC592-8050-41A9-9D27-49812A23D48E
P2860
Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis.
@en
Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis.
@nl
type
label
Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis.
@en
Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis.
@nl
prefLabel
Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis.
@en
Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis.
@nl
P2093
P356
P1433
P1476
Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis.
@en
P2093
Alexey Boyko
GALA Study Group
Krzysztof Selmaj
Peter Rieckmann
P304
P356
10.1002/ANA.23938
P577
2013-06-28T00:00:00Z